Selection of oral bioavailability enhancing formulations during drug discovery

The objective of this paper was to identify oral bioavailability enhancing approaches for a poorly water-soluble research compound during drug discovery stages using minimal amounts of material. LCQ789 is a pBCS (preclinical BCS) Class II compound with extremely low aqueous solubility (

Saved in:
Bibliographic Details
Published in:Drug development and industrial pharmacy 2012-02, Vol.38 (2), p.235-247
Main Authors: Zheng, Weijia, Jain, Akash, Papoutsakis, Dimitris, Dannenfelser, Rose-Marie, Panicucci, Riccardo, Garad, Sudhakar
Format: Article
Language:English
Subjects:
Administration, Oral
Animals
bioavailability
Biological Availability
Chemistry, Pharmaceutical - methods
co-crystal
Crystallization
Dogs
Drug Carriers - chemistry
Drug Discovery - methods
high-throughput screening
lipid-based delivery
Lipids - chemistry
Particle Size
Permeability
Physical form
Pyrazoles - chemistry
Pyrazoles - pharmacokinetics
Pyrimidinones - chemistry
Pyrimidinones - pharmacokinetics
Rats
solid dispersion
Solubility
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this paper was to identify oral bioavailability enhancing approaches for a poorly water-soluble research compound during drug discovery stages using minimal amounts of material. LCQ789 is a pBCS (preclinical BCS) Class II compound with extremely low aqueous solubility (
ISSN:0363-9045
1520-5762
DOI:10.3109/03639045.2011.602406